Zymeworks Inc (ZYME) has issued an update.
Zymeworks Inc. has announced the departure of Dr. Christopher Astle as Senior Vice President and Chief Financial Officer, effective from March 31, 2024. Recognizing his contributions to the company’s financial restructuring during his tenure, Zymeworks has agreed to a separation package, including a year’s base salary and benefits continuation. Dr. Astle is also granted a 90-day period to exercise vested stock options post-separation, while forfeiting any unvested stock options and restricted stock units. He remains subject to confidentiality and non-compete agreements as part of the severance terms.
Find detailed analytics on ZYME stock on TipRanks’ Stock Analysis page.
